The disclosure relates to compounds of formula (I) useful in the treatment of tauopathies and Alzheimer's disease

##STR00001##

wherein A, R, W, Q, n, and m are described herein.

A microneedle device of the present invention comprises a substrate, microneedles disposed on the substrate, and a coating formed on the microneedles, wherein the coating comprising dexmedetomidine or a pharmaceutically acceptable salt thereof and isoproterenol or a pharmaceutically acceptable salt thereof. Using said microneedle device, a fast increase rate of dexmedetomidine concentration in plasma after application of the microneedle device is achieved.

A composition for treating insomnia and related disorders is disclosed. The composition may include: (i) at least one polar lipid comprising at least one poly-unsaturated fatty acid (PUFA) moiety and (ii) Cannabidiol (CBD) or a derivative thereof.

A composition for treating insomnia and related disorders is disclosed. The composition may include: (i) at least one polar lipid comprising at least one poly-unsaturated fatty acid (PUFA) moiety and (ii) Cannabidiol (CBD) or a derivative thereof.

It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.

Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.

Provided are novel compounds of Formula (I): ##STR00001##
pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.

The present technology generally relates to compositions comprising at least one purified cannabinoid or a derivative thereof, and at least one functional fragrance. The present technology also generally relates to methods of using the compositions for, inter alia, improving sleep, for treating insomnia and/or related sleep disorders.